Endpoints
itching, Eczema, neurodermatitis
DISEASE, ECZEMA, ATOPIC DERMATITIS, NEURODERMATITIS
No primary endpoint was defined, due to the exploratory nature of this trial. The most important endpoint was considered the average subjectively perceived itching intensity within the last seven days measured after 16 weeks on a horizontal visual analogue scale (VAS; 0–100 mm), as it is validated and broadly used in AD trials.The measurements at baseline and after 8, 16, and 26 weeks were as follows: The average subjectively perceived itching intensity within the last seven days on a VASAt baseline and after 8 and 16 weeks, independent raters (physicians and nurses who are neurodermatitis trainers and specialized in SCORing Atopic Dermatitis [SCORAD] rating) performed a group allocation-blinded assessment of the disease severity using the broadly used and validated SCORAD and Eczema Area and Severity Index (EASI).At baseline, patients provided sociodemographic data and rated their expectations regarding study interventions on a numeric rating scale (nonvalidated). After 8, 16, and 26 weeks, patients allocated to HTP, IFDP, or EP reported their perceived efficacy of the respective treatment and all patients reported their self-perceived change of complaints. During the first 16 weeks, all patients recorded their medication and data on compliance to allocated interventions in diaries.Safety was assessed by AEs recorded in patients' diaries and/or in the study center.Further details on endpoints (range, minimal clinically important difference) are provided in All data were collected pseudonymously by standardized paper forms and entered in the SoSci Survey.